Galectin Therapeutics (GALT) Expected to Announce Quarterly Earnings on Tuesday

Galectin Therapeutics (NASDAQ:GALT) is projected to announce its Q2 2025 earnings results before the market opens on Tuesday, August 12th. Analysts expect the company to announce earnings of ($0.16) per share for the quarter.

Galectin Therapeutics (NASDAQ:GALT) last announced its quarterly earnings results on Thursday, May 15th. The company reported ($0.15) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.20) by $0.05. On average, analysts expect Galectin Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Galectin Therapeutics Stock Up 8.1%

GALT opened at $4.15 on Friday. The stock has a market capitalization of $262.65 million, a price-to-earnings ratio of -5.76 and a beta of 0.82. The firm has a 50 day moving average price of $2.50 and a 200-day moving average price of $1.78. Galectin Therapeutics has a twelve month low of $0.73 and a twelve month high of $4.41.

Institutional Investors Weigh In On Galectin Therapeutics

A hedge fund recently raised its stake in Galectin Therapeutics stock. Bank of America Corp DE grew its stake in Galectin Therapeutics Inc. (NASDAQ:GALT) by 101.4% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 38,358 shares of the company’s stock after buying an additional 19,316 shares during the quarter. Bank of America Corp DE owned approximately 0.06% of Galectin Therapeutics worth $49,000 as of its most recent SEC filing. Institutional investors own 11.68% of the company’s stock.

Analyst Ratings Changes

GALT has been the subject of a number of research reports. Wall Street Zen upgraded shares of Galectin Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, June 21st. HC Wainwright initiated coverage on Galectin Therapeutics in a research report on Tuesday, June 17th. They set a “buy” rating and a $6.00 price objective for the company.

Galectin Therapeutics Company Profile

Galectin Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma.